GeneTether Therapeutics Inc. Share Price
Equities
GTTX
CA37187D1087
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.045 CAD | -.--% | -.--% | +12.50% |
Sales 2022 | - | Sales 2023 | - | Capitalization | 1.17M 1.6M 93.37M |
---|---|---|---|---|---|
Net income 2022 | -1M -1.37M -79.87M | Net income 2023 | - 0 0 | EV / Sales 2022 | - |
Net cash position 2022 | 1.8M 2.46M 143M | Net cash position 2023 | 1.36M 1.87M 109M | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.84
x | P/E ratio 2023 |
-2.03
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 22.49% |
3 months | -10.00% | ||
6 months | +28.57% | ||
Current year | +12.50% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 70 | 11/02/18 | |
Roland Boivin
CEO | Chief Executive Officer | 57 | 30/09/21 |
Jean Jen
DFI | Director of Finance/CFO | 37 | 30/09/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Garner William
FOU | Founder | 58 | 11/02/18 |
Roland Boivin
CEO | Chief Executive Officer | 57 | 30/09/21 |
Gage Jull
BRD | Director/Board Member | 64 | 30/09/21 |
Date | Price | Change | Volume |
---|
Delayed Quote Canadian Securities Exchange, April 16, 2024 at 02:30 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+12.50% | 1.28M | |
+20.13% | 46.81B | |
-0.93% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.69% | 26.06B | |
-19.68% | 19.13B | |
+32.76% | 12.39B | |
+0.22% | 12.08B | |
-0.31% | 11.96B |
- Stock Market
- Equities
- GTTX Stock